Temple University

Other

Pfizer Corporation

Tully J Speaker

Tycho J Speaker

Paul A Offit

John H Collett

Frank N Chang

H Fred Clark

Manuel Campos

Stephen C Hsu

Fred M Clark

Mani R Sundararajan

Kenneth J Sultzbaugh

Patrick J Frenchick

Lawrence J Lesko

Charlotte A Moser

The present invention relates to microcapsules comprising a wall and an aqueous core comprising various active agents, and prepared by the interfacial reaction in aqueous medium of Lewis acid and base wall-forming reactants.

Aqueous solven encapsulation method, apparatus and microcapsules

A microencapsulated subunit component from bovine herpes virus-1 (BHV-1) is disclosed. Vaccines, kits, and methods for using the same to vaccinate a member of a bovine species are also disclosed.

Aqueous solvent based encapsulation of a bovine herpes virus type-1 subunit vaccine

An aqueous core microcapsule has a capsular wall provided with a peptide(s) of pre-determined binding specificity(ies) appended to the surface, the wall being the reaction product of an anionic polymer or salt thereof and a polyamine, salt thereof, mixtures thereof, or mixtures thereof with monoamines. The aqueous core may contain an active ingredient(s), and be targeted for delivery to specific cell tissues. The microcapsules are provided as a composition and in a kit with instructions for use in imaging, diagnosis, therapy, vaccination, and other applications.

Microcapsules of predetermined peptide(s) specificity (ies), their

Encapsulated perfluorocarbons

An artificial blood substitute comprising Lewis acid--Lewis base salt film microcapsule having a perfluorocarbon encapsulated therein. The Lewis base may be a polyoxyalkylene adduct of an amine and the Lewis acid may be a polyoxyalkylene derivative of a polymeric acid.

Salt film encapsulated perfluorocarbons

A microcapsule comprising an aqueous core, and capsular membrane formed from the interfacial reaction product of a hydrophilic polymeric Lewis acid or salt thereof with a lipophilic Lewis base or salt thereof.

Aqueous core microcapsules and method for their preparation

Improved sustained-release delivery forms comprising Lewis acid-Lewis base salt microparticulate material modified by the addition of at least one additional constituent known as an 'adjuvant' selected from the group consisting of carbomers, poloxamers and tetronomers. Adjuvants may assist in the manufacture of the microparticle or may provide additional advantageous characteristics such as assisting in solubilizing a core material or forming of the microparticle wall or both. Adjuvant modified microparticles have improved controlled release characteristics, have greater mechanical and thermal stability and have increased capacity for a wide range of core materials. In general, adjuvants are polyether linkage-containing molecules, adapted by virtue of their otherwise strongly acidic (carbomers or other water soluble compounds with pKa of less than 5), strongly basic (tetronomers or other non-aqueous solvent soluble bases with a pKa of more than 9 or above) or essentially neutral, but extremely weakly basic characteristics (poloxamers or other non-aqueous solvent soluble compounds with a pKa of from 5 to 7) to function as wall-forming or core-forming reactants in the microcapsule-forming reaction of this invention.

Adjuvant-enhanced sustained release composition and method for making

Delivery system for topical application comprising a highly viscous carrier containing dissolved or dispersed and microencapsulated topically-active agents providing immediate and sustained release of the topically-active agent to localized body sites.

Encapsulated topical delivery system

Sustained-released delivery forms comprising the reaction product of a Lewis acid salt with a Lewis base salt at the phase interface of their respective aqueous and non-aqueous solution to form an anisotropic high molecular weight salt of the acid and base and a neutral salt of the inorganic cation and anion in what is termed a 'double decomposition' or 'salt exchange' reaction.

Production of sustained release composition from salt-form reactants

Lewis acid-Lewis base high molecular weight salt microparticulate material of the type referred to in U.S. Pat. No. 3,959,457, which include biologically active peptides and proteins solubilized in a non-aqueous, non-denaturing manufacturing solvent.

Sustained release protein compositions and method for making

In a finely dispersed emulsion of a water immiscible solution of an organic polyfunctional Lewis base and an aqueous solution of a partially hydrophilic, partially lipophilic polyfunctional Lewis acid, a reaction occurs at the phase interface to produce a novel microparticulate material comprised of the reaction product of the Lewis acid and the Lewis base. The maximum particle size dimensions of the microparticulate material depends on the degree of dispersion in the emulsified reaction mixture and may be as low as 2 microns or smaller.

Growing community of inventors

Philadelphia, PA, United States of America

Tully J Speaker